^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:AiRuiKang (dalpiciclib) (CDK4 inhibitor, CDK6 inhibitor) +
    famitinib (SHR 1020) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

    Excerpt:
    ...- HR-positive, HER2- negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline)....
    Trial ID:
    NCT05176080
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SABCS 2023
    Title:

    Famitinib, a multi-targeted receptor tyrosine kinase inhibitor, combined with dalpicilib and fulvestrant in advanced HR-positive and HER2-negative breast cancer

    Published date:
    12/02/2023
    Excerpt:
    Overall 10 pts (55.6%) achieved confirmed partial responses and 16 (88.9%) achieved clinical benefits….The anti-angiogenesis multi-targeted receptor TKI famitinib combined with CDK4/6i and fulvestrant has shown antitumor effects in advanced HR-positive and HER2-negative BC, and no new safety signals were observed.
    Secondary therapy:
    fulvestrant
    Trial ID:
    NCT05176080